These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 31536101)

  • 1. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.
    Rosenstock J; Kahn SE; Johansen OE; Zinman B; Espeland MA; Woerle HJ; Pfarr E; Keller A; Mattheus M; Baanstra D; Meinicke T; George JT; von Eynatten M; McGuire DK; Marx N;
    JAMA; 2019 Sep; 322(12):1155-1166. PubMed ID: 31536101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
    Rosenstock J; Perkovic V; Johansen OE; Cooper ME; Kahn SE; Marx N; Alexander JH; Pencina M; Toto RD; Wanner C; Zinman B; Woerle HJ; Baanstra D; Pfarr E; Schnaidt S; Meinicke T; George JT; von Eynatten M; McGuire DK;
    JAMA; 2019 Jan; 321(1):69-79. PubMed ID: 30418475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin: A Secondary Analysis of Randomized Clinical Trials.
    Marx N; Kolkailah AA; Rosenstock J; Johansen OE; Cooper ME; Alexander JH; Toto RD; Wanner C; Espeland MA; Mattheus M; Schnaidt S; Perkovic V; Gollop ND; McGuire DK
    JAMA Cardiol; 2024 Feb; 9(2):134-143. PubMed ID: 38170502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®).
    Marx N; Rosenstock J; Kahn SE; Zinman B; Kastelein JJ; Lachin JM; Espeland MA; Bluhmki E; Mattheus M; Ryckaert B; Patel S; Johansen OE; Woerle HJ
    Diab Vasc Dis Res; 2015 May; 12(3):164-74. PubMed ID: 25780262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulfonylurea glimepiride on cardiovascular outcomes in Asians with type 2 diabetes: subgroup analysis of the randomized CAROLINA® trial.
    Kadowaki T; Wang G; Rosenstock J; Yabe D; Peng Y; Kanasaki K; Mu Y; Mattheus M; Keller A; Okamura T; Johansen OE; Marx N
    Diabetol Int; 2021 Jan; 12(1):87-100. PubMed ID: 33479584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial.
    Espeland MA; Pratley RE; Rosenstock J; Kadowaki T; Seino Y; Zinman B; Marx N; McGuire DK; Andersen KR; Mattheus M; Keller A; Weber M; Johansen OE
    Diabetes Obes Metab; 2021 Feb; 23(2):569-580. PubMed ID: 33185002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.
    Jax T; Stirban A; Terjung A; Esmaeili H; Berk A; Thiemann S; Chilton R; von Eynatten M; Marx N
    Cardiovasc Diabetol; 2017 Jan; 16(1):13. PubMed ID: 28109295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study.
    Biessels GJ; Verhagen C; Janssen J; van den Berg E; Wallenstein G; Zinman B; Espeland MA; Johansen OE
    Diabetologia; 2021 Jun; 64(6):1235-1245. PubMed ID: 33559704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.
    Gallwitz B; Rosenstock J; Rauch T; Bhattacharya S; Patel S; von Eynatten M; Dugi KA; Woerle HJ
    Lancet; 2012 Aug; 380(9840):475-83. PubMed ID: 22748821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA
    Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK;
    Cardiovasc Diabetol; 2018 Mar; 17(1):39. PubMed ID: 29540217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Linagliptin versus glimepiride add-on for the long-term treatment of Type 2 diabetes mellitus.
    Chilton R
    Expert Rev Endocrinol Metab; 2013 Jul; 8(4):345-349. PubMed ID: 30736150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus.
    Biessels GJ; Janssen J; van den Berg E; Zinman B; Espeland MA; Mattheus M; Johansen OE;
    BMC Neurol; 2018 Jan; 18(1):7. PubMed ID: 29334906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using Real-World Data to Predict Findings of an Ongoing Phase IV Cardiovascular Outcome Trial: Cardiovascular Safety of Linagliptin Versus Glimepiride.
    Patorno E; Schneeweiss S; Gopalakrishnan C; Martin D; Franklin JM
    Diabetes Care; 2019 Dec; 42(12):2204-2210. PubMed ID: 31239281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incident and recurrent hypoglycaemia with linagliptin and glimepiride over a median of 6 years in the CAROLINA cardiovascular outcome trial.
    Rosenstock J; Kolkailah AA; McGuire DK; Espeland MA; Mattheus M; Pfarr E; Lund SS; Marx N;
    Diabetes Obes Metab; 2023 Jun; 25(6):1453-1463. PubMed ID: 36700416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.
    McGuire DK; Alexander JH; Johansen OE; Perkovic V; Rosenstock J; Cooper ME; Wanner C; Kahn SE; Toto RD; Zinman B; Baanstra D; Pfarr E; Schnaidt S; Meinicke T; George JT; von Eynatten M; Marx N;
    Circulation; 2019 Jan; 139(3):351-361. PubMed ID: 30586723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
    Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
    Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA).
    Christensen AS; Hædersdal S; Støy J; Storgaard H; Kampmann U; Forman JL; Seghieri M; Holst JJ; Hansen T; Knop FK; Vilsbøll T
    Diabetes Care; 2020 Sep; 43(9):2025-2033. PubMed ID: 32661107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postprandial renal haemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes (RENALIS): A predefined substudy of a randomized, double-blind trial.
    Muskiet MHA; Tonneijck L; Smits MM; Kramer MHH; Ouwens DM; Hartmann B; Holst JJ; Danser AHJ; Joles JA; van Raalte DH
    Diabetes Obes Metab; 2022 Jan; 24(1):115-124. PubMed ID: 34580975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linagliptin in patients with type 2 diabetes and cardiovascular and/or renal disease: results from a cardiovascular and renal outcomes trial.
    Guthrie R
    Postgrad Med; 2020 May; 132(4):314-319. PubMed ID: 32164494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8-week, randomized, controlled, double-blind trial.
    Kraaijenhof J; Muskiet MHA; Tonneijck L; Ouwens DM; Kramer MHH; van Raalte DH; Smits MM
    Diabetes Obes Metab; 2020 Oct; 22(10):1847-1856. PubMed ID: 32476255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.